Financiere des Professionnels Fonds d investissement inc. Makes New $2.19 Million Investment in Abbott Laboratories $ABT

Financiere des Professionnels Fonds d investissement inc. acquired a new stake in Abbott Laboratories (NYSE:ABT) during the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 21,282 shares of the healthcare product maker’s stock, valued at approximately $2,185,000.

A number of other hedge funds also recently modified their holdings of ABT. Bessemer Group Inc. boosted its holdings in shares of Abbott Laboratories by 1.6% during the 1st quarter. Bessemer Group Inc. now owns 1,013,900 shares of the healthcare product maker’s stock worth $104,098,000 after buying an additional 16,135 shares during the period. Gerald Baker Financial Group LLC bought a new position in Abbott Laboratories in the 1st quarter valued at about $922,000. Allspring Global Investments Holdings LLC lifted its position in Abbott Laboratories by 11.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 468,676 shares of the healthcare product maker’s stock worth $47,983,000 after acquiring an additional 50,017 shares during the last quarter. One Day In July LLC boosted its holdings in shares of Abbott Laboratories by 3.6% during the first quarter. One Day In July LLC now owns 3,669 shares of the healthcare product maker’s stock worth $377,000 after acquiring an additional 127 shares during the period. Finally, Independent Financial Group LLC acquired a new position in shares of Abbott Laboratories in the first quarter valued at approximately $1,545,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ABT has been the subject of several research reports. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Barclays decreased their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Piper Sandler reissued an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday. Raymond James Financial reduced their target price on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, BTIG Research raised their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $100.71 on Friday. The firm has a 50 day moving average of $89.89 and a 200-day moving average of $102.17. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $175.41 billion, a PE ratio of 32.59, a PEG ratio of 1.70 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period last year, the firm posted $1.26 earnings per share. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.